Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.

Pancreatic cancer had a very low survival rate and was hard to treat effectively.

Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.

Aumolertinib effectively controls lung cancer and improves quality of life.

The treatment combination is effective and generally safe for lung cancer.

Nilotinib can cause keratosis pilaris, a skin condition.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Nilotinib can cause skin issues like red bumps and hair loss.

Nilotinib can cause generalized keratosis pilaris.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

The combination treatment showed a higher response rate but no significant survival benefits.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Nilotinib may cause gray hair to return to its original color.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

A man developed skin issues from cancer medication, which improved with specific treatments.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.